Is Accretion Pha. overvalued or undervalued?

As of 14 November 2025, the valuation grade for Accretion Pharma has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued. Key ratios include a PE Ratio of 11.21, an EV to EBITDA of 7.59, and a Price to Book Value of 4.98, which are notably high compared to its peers.
In comparison, Sun Pharma has a PE Ratio of 36.49 and an EV to EBITDA of 24.09, while Divi's Lab shows a PE Ratio of 69.65 and an EV to EBITDA of 52.35, both categorized as very expensive. This suggests that Accretion Pharma's valuation metrics, while high, are not as extreme as some of its competitors. Despite recent stock performance showing a 19.76% return over the past week compared to a 1.64% return for the Sensex, the overall valuation still points towards overvaluation in the current market context.